Ebola Vaccine Trial Begins in DR Congo as Bundibugyo Outbreak Grows

A new trial begins at the outbreak’s epicenter

The first participants have been vaccinated in a clinical trial aimed at finding protection against the Ebola virus species driving the Democratic Republic of Congo’s current epidemic. The trial, called Tumaini—Swahili for “hope”—began in Bunia, the capital of Ituri province, where the outbreak is centered.

The trial matters because the virus involved is Bundibugyo ebolavirus, not the more common Zaire ebolavirus targeted by the approved Ebola vaccine Ervebo. The outbreak has passed 9,700 reported cases and more than 4,600 deaths, according to the report. With no approved vaccine or treatment specifically for the Bundibugyo species, health authorities are seeking evidence that can inform the response while cases continue.

World Health Organization Director-General Tedros Adhanom Ghebreyesus said the first vaccinations marked the start of a DRC-led effort supported by WHO. The immediate objective is to determine whether vaccine candidates can safely generate useful protection against Bundibugyo virus and, ultimately, whether they can help curtail transmission.

Why Ervebo is being tested

Ervebo is already approved against Zaire ebolavirus, but it has not been approved for Bundibugyo ebolavirus. In the Tumaini trial, Ervebo will be tested in a full-scale human study to assess whether it provides cross-protection against the species behind the epidemic.

That distinction is central to the study. Ebola vaccines are not automatically interchangeable across virus species. A vaccine designed and approved for one species may not deliver the same level of protection against another. The trial is intended to replace uncertainty with direct evidence gathered in the setting where exposure risk is highest.

For the outbreak response, an answer on cross-protection could be operationally important. If Ervebo demonstrates useful protection, it could provide an evidence-based option while Bundibugyo-specific candidates continue to advance. If it does not, the finding would be equally consequential for how responders prioritize the next tools.

A platform for several vaccines

Tumaini is structured as a single trial framework that can evaluate the safety, efficacy and immunogenicity of multiple vaccines. That design allows the program to incorporate more than one candidate rather than treating each potential vaccine as an entirely separate effort.

Two vaccine candidates designed for Bundibugyo virus are expected to enter the framework after progressing through earlier, smaller clinical studies. One is a ChAdOx1 adenoviral-vector vaccine being developed by the University of Oxford. The other is an mRNA-based candidate from Moderna. Both have received funding from the Coalition for Epidemic Preparedness Innovations, or CEPI.

The trial’s ability to add candidates is especially significant in an active outbreak. It creates a route for comparing or assessing emerging options as the evidence base changes, instead of assuming that an existing product aimed at a different Ebola species will be sufficient.

Ring vaccination focuses on exposure risk

The study will use a ring-vaccination approach. Rather than vaccinating a broad population at random, the strategy immunizes contacts considered at high risk of infection. Such an approach is designed around the chains of exposure that can drive an outbreak, concentrating vaccination where it may have the greatest immediate relevance.

CEPI said Tumaini will work with affected communities, health authorities and outbreak-response partners to generate robust evidence on vaccine performance. The trial is also set to include pregnant women, broadening the population represented in the evidence collected during the response.

That community-facing element is not peripheral. A vaccine study during an outbreak depends on identifying people at risk, explaining the study and maintaining coordination with local health systems. The trial is therefore both a research program and part of the wider public-health effort underway in Ituri province.

What the trial can and cannot answer

The launch of Tumaini does not mean a Bundibugyo-specific vaccine has already been proven effective. The trial is beginning precisely because those answers are still needed. Its findings will have to establish how the vaccines perform in the relevant population and outbreak conditions.

It also does not resolve the immediate burden of the epidemic on its own. Vaccination is one component of outbreak response, alongside the work of affected communities, health authorities and response partners. Still, the study gives the response a mechanism to turn a major gap—no approved vaccine or treatment for this Ebola species—into a testable set of options.

For now, the practical significance is that a formal pathway is operating at the heart of the outbreak: Ervebo will be assessed for cross-protection, and two species-specific candidates are expected to join the trial. The results could influence both the current response and preparedness for future Bundibugyo outbreaks.

This article is based on reporting by Medical Xpress. Read the original article.